Current Recommendations for Laboratory Testing and Use of Bone Turnover Markers in Management of Osteoporosis

키워드

참고문헌 (63)

1. "Consensus Development Conference: diagnosis, prophylaxis and treatment of osteoporosis", Am J Med, 94, pp.646~650 (1993)
2. Kanis JA, "A reference standard for the description of osteoporosis", Bone, 42, pp.467~475 (2008)
3. Lim S, "Incidence of hip fractures in Korea", Journal of Bone and Mineral Metabolism, 26(4), pp.400~405 (2008), Springer Verlag
4. Moon YW, "Mortality, second fracture, and functional recovery after hip fracture surgery in elderly Koreans", Korean J Bone Metab, 15, pp.41~47 (2008)
5. 이성락, "고관절 주위골절로 인한 사망률 및 활동성 -전향적 연구-", 대한정형외과학회지, 40(4), pp.423~427 (2005), 대한정형외과학회
6. 고덕환, "고령 환자에서 고관절부 골절의 수술 후 사망률", 대한골절학회지, 19(2), pp.1~1 (2006), 대한골절학회
7. "Statistics Korea"[URL]
8. Cooper C, "Secular trends in the incidence of hip and other osteoporotic fractures", Osteoporos Int, 22, pp.1277~1288 (2011)
9. Cooper C, "Hip fractures in the elderly: a world-wide projection", Osteoporos Int, 2, pp.285~289 (1992)
10. Kanis JA, "FRAX and the assessment of fracture probability in men and women from the UK", Osteoporos Int, 19, pp.385~397 (2008)
11. 이동윤, "Determination of an Applicable FRAX Model in Korean Women", Journal of Korean Medical Science, 25(11), pp.1657~1660 (2010), 대한의학회
12. Tromp AM, "Predictors of fractures in elderly women", Osteoporos Int, 11, pp.134~140 (2000)
13. Ross PD, "Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study", Osteoporos Int, 11, pp.76~82 (2000)
14. van Daele PL, "Case-control analysis of bone resorption markers, disability, and hip fracture risk: the Rotterdam study", BMJ, 312, pp.482~483 (1996)
15. Chapurlat RD, "Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: the EPIDOS study", Bone, 27, pp.283~286 (2000)
16. Garnero P, "Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY Study", J Bone Miner Res, 15, pp.1526~1536 (2000)
17. Greenfield DM, "The association between bone turnover and fracture risk: The Sheffield Osteoporosis study", pp.225~226 (2001), Lavoisier
18. Garnero P, "Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study", J Bone Miner Res, 17, pp.826~833 (2002)
19. Meier C, "Bone resorption and osteoporotic fractures in elderly men: the dubbo osteoporosis epidemiology study", J Bone Miner Res, 20, pp.579~587 (2005)
20. Bauer DC, "Biochemical markers of bone turnover, hip bone loss, and fracture in older men: the MrOS study", J Bone Miner Res, 24, pp.2032~2038 (2009)
21. Vasikaran S, "Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards", Osteoporos Int, 22, pp.391~420 (2011)
22. Veitch SW, "Changes in bone mass and bone turnover following tibial shaft fracture", Osteoporos Int, 17, pp.364~372 (2006)
23. Ingle BM, "Changes in bone mass and bone turnover following ankle fracture", Osteoporos Int, 10, pp.408~415 (1999)
24. Lane NE, "The science and therapy of glucocorticoid-induced bone loss", Endocrinol Metab Clin North Am, 27, pp.465~483 (1998)
25. Deodhar AA, "Bone mass measurement and bone metabolism in rheumatoid arthritis: a review", Br J Rheumatol, 35, pp.309~322 (1996)
26. "Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older men (RACGP)"[URL]
27. Ross AC, "The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know", J Clin Endocrinol Metab, 96, pp.53~58 (2011)
28. Glendenning P, "Current assays overestimate 25-hydroxyvitamin D3 and underestimate 25-hydroxyvitamin D2 compared with HPLC: need for assay-specific decision limits and metabolite-specific assays", Ann Clin Biochem, 43, pp.23~30 (2006)
29. Glendenning P, "Parathyroid hormone is more stable in EDTA plasma than in serum", Clin Chem, 48, pp.766~767 (2002)
30. 정수호, "부천 지역 폐경 여성에서 비타민 D 상태와 골밀도의 연관성", OSTEOPOROSIS, 7(3), pp.198~202 (2009), 대한골다공증학회
31. Kim H, "A study on vitamin D insufficiency in postmenopausal Korean women", J Korean Society Osteoporos, 1, pp.12~21 (2003)
32. Park HM, "The vitamin D nutritional status of postmenopausal women in Korea", Korean J Bone Metab, 10, pp.47~55 (2003)
33. 소재성, "한국 폐경 여성에서 부갑상선 호르몬, 비타민 D와골대사 사이의 관계", Obstetrics & Gynecology Science, 47(1), pp.153~160 (2004), 대한산부인과학회
34. Brown JP, "Bone turnover markers in the management of postmenopausal osteoporosis", Clin Biochem, 42, pp.929~942 (2009)
35. Koivula MK, "Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide", Ann Clin Biochem, 47, pp.67~71 (2010)
36. Marin L, "Comparison of total and intact aminoterminal propeptide of type I procollagen assays in patients with breast cancer with or without bone metastases", Ann Clin Biochem, 48, pp.447~451 (2011)
37. Douglas DL, "Effect of dichloromethylene diphosphonate in Paget’s disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease", Lancet, 1, pp.1043~1047 (1980)
38. Fraser WD, "Direct and indirect assessment of the parathyroid hormone response to pamidronate therapy in Paget’s disease of bone and hypercalcaemia of malignancy", Bone Miner, 12, pp.113~121 (1991)
39. Chesnut CH, "Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women", Osteoporosis Int, 3(S3), pp.S17~S19 (1993)
40. Maalouf NM, "Bisphosphonate- induced hypocalcemia: report of 3 cases and review of literature", Endocr Pract, 12, pp.48~53 (2006)
41. McCloskey EV, "Diphosphonates and phosphate homeostasis in man", Clin Sci, 74, pp.607~612 (1988)
42. Vasikaran SD, "The effect of alendronate on renal tubular reabsorption of phosphate", Bone Miner, 27, pp.51~56 (1994)
43. Jodrell DI, "Symptomatic hypocalcaemia after treatment with high-dose aminohydroxypropylidene diphosphonate", Lancet, 1, pp.622~ (1987)
44. Chong G, "Symptomatic hypocalcaemia following intravenous pamidronate in cancer patients", Aust N Z J Med, 29, pp.96~97 (1999)
45. Garnero P, "Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment", J Clin Endocrinol Metab, 79, pp.1693~1700 (1994)
46. Schlosser K, "Biochemical markers as surrogates in clinical trials in patients with metastatic bone disease and osteoporosis", Scand J Clin Lab Invest Suppl, 227, pp.21~28 (1997)
47. Braga de Castro Machado A, "Monitoring alendronate therapy for osteoporosis", J Bone Miner Res, 14, pp.602~608 (1999)
48. Bell NH, "Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women", J Clin Endocrinol Metab, 87, pp.2792~2797 (2002)
49. Greenspan SL, "Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial", J Bone Miner Res, 13, pp.1431~1438 (1998)
50. Garnero P, "Different effects of bisphosphonate and estrogen therapy on free and peptidebound bone cross-links excretion", J Bone Miner Res, 10, pp.641~649 (1995)
51. Rosen HN, "Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover", Calcif Tissue Int, 54, pp.26~29 (1994)
52. Rosen HN, "Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates", Calcif Tissue Int, 63, pp.363~368 (1998)
53. McClung MR, "Denosumab in postmenopausal women with low bone mineral density", N Engl J Med, 354, pp.821~831 (2006)
54. Rosen CJ, "Treatment with once-weekly alendronate 70 mg compared with onceweekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study", J Bone Miner Res, 20, pp.141~151 (2005)
55. McClung MR, "Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass", Arch Intern Med, 165, pp.1762~1768 (2005)
56. with alendronate in postmenopausal women with osteoporosis, "J Clin Endocrinol Metab", 2002, 4528~4535
57. Meunier PJ, "The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis", N Engl J Med, 350, pp.459~468 (2004)
58. Bergmann P, "Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club", Int J Clin Pract, 63, pp.19~26 (2009)
59. Riggs BL, "Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover and increases in bone mass both determine antifracture efficacy", Bone, 18(S3), pp.197S~201S (1996)
60. Delmas PD, "Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy", Bone, 34, pp.599~604 (2004)
61. Delmas PD, "Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs", Osteoporos Int, 11(S6), pp.S66~S76 (2000)
62. Hannon R, "Preanalytical variability of biochemical markers of bone turnover", Osteoporos Int, 11(S6), pp.S30~S44 (2000)
63. Eastell R, "Development of an algorithm for using PINP to monitor treatment of patients with teriparatide", Curr Med Res Opin, 22, pp.61~66 (2006)

관련 논문AI추천